Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 3Gynecologic 2Sarcoma 1Lymphoid 1Head & Neck 1CNS 1Breast 1

Conditions

Stomach Neoplasms 1Stomach Diseases 1Head and Neck Neoplasms 1Gastrointestinal Neoplasms 1Gastrointestinal Diseases 1Esophageal Neoplasms 1Esophageal Diseases 1Digestive System Neoplasms 1Digestive System Diseases 1

Interventions

pembrolizumab 166Cisplatin 112Cetuximab 76Nivolumab 52Carboplatin 51Fluorouracil 48Paclitaxel 42Docetaxel 37Gemcitabine 30Radiotherapy 28Capecitabine 19Cyclophosphamide 18durvalumab 17Injections 17lenvatinib 16atezolizumab 16cemiplimab 15spartalizumab 13fludarabine 13avelumab 12Ipilimumab 12Pemetrexed 11130-nm albumin-bound paclitaxel 11Oxaliplatin 10Gefitinib 10tremelimumab 9Drug Therapy 9tislelizumab 8epacadostat 8budigalimab 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Ocoxin × Head & Neck × Clear all
NCT03549494 2024-02-07

Evaluation of Ocoxin®-Viusid® in Advanced Stomach Cancer and Gastric Esophagogastric Junction

Catalysis SL

Phase 2 Completed
45 enrolled
GastrointestinalHead & Neck

Digestive System Diseases, Digestive System Neoplasms, Esophageal Diseases, Esophageal Neoplasms, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Stomach Diseases, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡